Arthur S. Przybyl is the President and Chief Executive Officer of ANI Pharmaceuticals, a pharmaceutical company. He holds a bachelor's degree in Pharmacy from the University of Minnesota, which laid the groundwork for his career in the healthcare industry. Since...

Arthur S. Przybyl is the President and Chief Executive Officer of ANI Pharmaceuticals, a pharmaceutical company. He holds a bachelor's degree in Pharmacy from the University of Minnesota, which laid the groundwork for his career in the healthcare industry. Since joining ANI in 2013, he has driven the company’s growth by focusing on performance and aligning executive goals with the interests of stakeholders. Arthur’s compensation is performance-based, with his total pay reaching nearly $4.2 million in 2018, including a significant cash bonus and stock options. It's clear he’s invested in the company's future—much of his wealth is tied to ANI's stock performance. He has consistently strategized to make ANI Pharmaceuticals adaptable and competitive in a tough market, emphasizing flexibility in executive compensation to attract and keep talent. Arthur's leadership style combines solid pharmaceutical knowledge with a business-oriented approach that emphasizes growth and sustainability, ultimately aiming to enhance shareholder value.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ANI Pharmaceuticals CEOs

A

Arthur S. Przybyl

Ex-CEO of ANI Pharmaceuticals

Education

B.S. in Business Administration from the University of Illinois

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1960 - 65 years ago

CEO of ANI Pharmaceuticals for

14 years 4 months (Jan 2006 - May 2020)

Previous Experience

CEO of Akorn, Inc.

Rivals

Competitors/colleagues of Arthur S. Przybyl

Holdings

See how much did Arthur S. Przybyl make over time.

Arthur S. Przybyl has considerable investments in ANI Pharmaceuticals. In 2018, he saw his total compensation peak at about $4.2 million, deeply tied to the company's performance. He received 29,100 shares of restricted stock valued at approximately $1.66 million, vesting...

Arthur S. Przybyl has considerable investments in ANI Pharmaceuticals. In 2018, he saw his total compensation peak at about $4.2 million, deeply tied to the company's performance. He received 29,100 shares of restricted stock valued at approximately $1.66 million, vesting over four years. As of his latest reports, his stock options, granted during pivotal years, showcase his dedication to the firm. This ties Arthur's financial success directly to the company’s fortunes. Early in his tenure, his compensation was notably lower, showing steady growth aligned with the company's progress. This aligns with the pattern of executives whose wealth often escalates along with the company’s market success, revealing a commitment to both personal and corporate achievement.

Mar 18, 2025

A

shares

ANIP @ $64.22

Total Stock Sold

$14.99M

ANIP

$14.99M

234,066 ANIP shares

What if they kept their stock?

If Arthur S. Przybyl didn't sell their stock, today they would have:
Extra ANIP234,066 shares worth $7.30M.
This is -51.27% and $7.68M less than what they got when they sold the stock.

Charitable Transactions

ANIP

6,306 shares

ANIP

Recent Charitable Transactions

ANIP

2,180 shares

ANIP

Dec 31, 2018

Charity

ANIP

850 shares

ANIP

Dec 31, 2017

Charity

ANIP

1,120 shares

ANIP

Mar 31, 2017

Charity

ANIP

836 shares

ANIP

Aug 9, 2016

Charity

ANIP

1,320 shares

ANIP

Dec 15, 2015

Charity

Insider Trading

See recent insider trades of Arthur S. Przybyl.

ANIP

$2.11M

ANIP at $70.27/share

May 13, 2019

Sale

ANIP

37,280 shares

ANIP

Mar 28, 2019

Received

ANIP

$1.75M

ANIP at $63.52/share

Mar 18, 2018

Sale

ANIP

2,180 shares

ANIP

Dec 31, 2018

Charity

ANIP

29,100 shares

ANIP

Apr 6, 2018

Received

ANIP

$2.48M

ANIP at $62.06/share

Mar 12, 2018

Sale

ANIP

$1.47M

ANIP at $61.46/share

Mar 1, 2018

Sale

ANIP

850 shares

ANIP

Dec 31, 2017

Charity

ANIP

23,750 shares

ANIP

Mar 31, 2017

Received

ANIP

1,120 shares

ANIP

Mar 31, 2017

Charity

Compensation History

See how much did Arthur S. Przybyl make over time.

In 2018, Arthur S. Przybyl earned a total compensation of $4,197,933 as CEO of ANI Pharmaceuticals. This included a base salary of $726,925 and a cash bonus of $675,000, reflecting 120% of his target bonus. Arthur also received significant stock awards: 29,100 shares of restricted stock worth approximately $1,660,446, which vest over four years. His stock options for 35,200 shares were granted at a price of $57.06 per share, indicating a robust compensation structure that aligns with the company’s performance metrics. This blend of salary, bonuses, and stock options illustrates a compensation strategy that rewards achievement and drives long-term company growth. Each year, his compensation grew, showing a solid connection between the company's market performance and executive rewards.

Year

2018

Total Compensation

$3.09M

Salary

$726.93K

Board Justification

The compensation program is designed to attract, retain, and motivate qualified executives while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$675.00K

Board Justification

Cash bonus of $675,000, which was 120% of the target bonus of 75% of his base salary for 2018.

Other

$30.63K

Board Justification

Includes a $10,000 automobile allowance and $20,634 in 401(k) matching contributions.

Restricted Stock

$1.66M(29.1K restricted common stock)

Board Justification

29,100 shares of restricted common stock, which vest in equal annual installments on the first, second, third and fourth anniversaries of the date of grant.

Performance Metrics

The annual cash bonus is based on the achievement of certain individual and corporate objectives.

Other ANI Pharmaceuticals CEOs

Here are other CEOs of ANI Pharmaceuticals

Patrick D. Walsh

Ex-CEO of ANI Pharmaceuticals

May 2020 - September 2020